

ASX Announcement
18 January 2019

Prime Minister announces easing of Kava Importation into Australia

Fiji Kava Limited (ASX:FIJ) (**Fiji Kava** or the **Company**), notes that on 16 January 2019, Australian Prime Minister, Scott Morrison announced during his recent trip to Vanuatu, that a pilot program will be put in place to ease some of the limitations of the importation of kava into Australia.

The announcement is a significant breakthrough for the kava industry and represents a growing acceptance of kava as a natural and safe alternative for managing stress and anxiety. This move aligns with Fiji Kava's efforts to make kava a new alternative to prescription medication, such as Valium and Xanax, currently representing a US\$15 billion global benzodiazepine market¹.

Fiji Kava Managing Director, Zane Yoshida, said:

"We are encouraged by the announcement made by Australian Prime Minister, Scott Morrison. This is certainly a step in the right direction and Fiji Kava looks forward the development of the pilot program."

A copy of the transcript can be found in the following link:

<https://www.pm.gov.au/media/joint-remarks-prime-minister-vanuatu-0>.

1. Source: Anxiety Disorders And Depression Treatment Market Analysis By Product (Antidepressant Drugs, SSRIs, SNRIs, Benzodiazepines, Devices And Therapy, TMS, DBS, VBS), By Indication (MDD, OCD, Phobia) and Segment Forecasts, 2014 – 2025. Kava Report 2003: In-Depth Investigation into EU Member States Market Restrictions on Kava Products.

Ends

For further information, please contact:

Media Enquiries

Hannah Howlett

Media and Capital Partners

P: 0450 648 064

E: hannah.howlett@mcpartners.com.au

About Fiji Kava

Fiji Kava is a kava company based in Australia and the first foreign company with approval from the Fijian Government to operate in the kava industry. The Company has complete control over its vertically integrated supply chain in a true farm-to-shelf operation and has established a 111-acre nucleus farm in Levuka, on the island of Ovalau, Fiji. Fiji Kava is focussed on expanding the distribution of kava throughout western markets to provide a natural alternative to anti-anxiety prescription medicines such as Valium and Xanax. The Company sells its range of TGA and FDA compliant "Taki Mai" branded kava products in Fiji and is preparing to launch under the Fiji Kava brand in Australia in early 2019. Fiji Kava's products are backed by years of independent research. The Company plans to conduct human clinical trials to test the efficacy of Fiji Kava's products and specific kava cultivars, targeting a range of medical conditions.

For personal use only